Laser Photonics Lands $1.05M Order for 70K-Tablet/Hour Laser Drilling

In controlled-release drug manufacturing, the difference between therapeutic efficacy and a recall can be a fraction of a millimeter in the orifice drilled into each tablet. CMS Laser's new $1.05M order from an undisclosed U.S. pharma manufacturer puts a 70,000-tablet/hour TD-70 line inside that high-stakes process, with dual-camera inspection and IQ/OQ/PQ documentation that positions the vendor as a GMP qualification partner.

On August 24, 2026, Laser Photonics Corporation (Nasdaq: LASE) announced through a press release that its subsidiary, CMS Laser, had received a purchase order valued at approximately $1.05 million from an undisclosed U.S.-based pharmaceutical manufacturer for a TD-70 high-speed pharmaceutical tablet drilling system. The order is described as a first-time purchase by this customer and marks CMS Laser's entry into a new pharmaceutical manufacturing account. Because the information traces to a corporate press release distribution rather than independent reporting, the order should be treated as an announced transaction whose final revenue recognition, installation, and qualification remain to be completed.

“

CMS Laser's new $1.05M order from an undisclosed U.S.

At the center of the transaction is the TD-70, a system designed to laser-drill the precision orifices that control how controlled-release oral medications deliver their active ingredients. In this application, a fraction of a millimeter can determine therapeutic performance, making the drilling process both a manufacturing step and a critical quality attribute. The TD-70's advertised throughput of up to 70,000 tablets per hour and its dual-camera vision system, which inspects every tablet twice and automatically rejects any unit outside specification before it moves downstream, directly address the twin requirements of high-volume production and pharmaceutical-grade quality control.

Notably, the order covers a complete production line rather than a single machine. CMS Laser is supplying tablet handling tooling and conveyor transport to integrate the platform into the customer's production flow, along with the full IQ, OQ, and PQ validation package and on-site installation by its own engineers. That scope is meaningful in a pharmaceutical context: Installation Qualification, Operational Qualification, and Performance Qualification are the documentary and testing backbone of a drug manufacturer's GMP quality system. By packaging validation support with the equipment, CMS Laser positions itself as a technical partner inside the customer's qualification process rather than a transactional equipment vendor. For a highly regulated end market, this support can materially reduce the time and risk involved in bringing new production equipment online.

The strategic significance of the order is greater than its modest dollar value. A $1.05 million capital equipment order is not transformative for a public company, but it represents an entry into pharmaceutical manufacturing, a sector known for long qualification cycles, demanding documentation, and high switching costs once equipment is validated. Laser Photonics already serves industrial and defense applications; this order extends its precision laser drilling franchise into a quality-intensive life-sciences environment. If the deployment is successful, the company has stated that it believes the engagement has the potential to support additional system orders, whether from the same customer's capacity expansion or from other manufacturers facing similar controlled-release production needs. That kind of repeat business would generate a higher-margin, service-rich revenue stream than one-off equipment sales.